TETRAPHASE PHARMACEUTICALS INC Deferred Tax Assets, in Process Research and Development
TETRAPHASE PHARMACEUTICALS INC had Deferred Tax Assets, in Process Research and Development of $11.27 million as of 2019-12-31, per its 10-K filed 2020-03-12.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2020-03-12
- 2019-12-31: Deferred Tax Assets, in Process Research and Development $11.27M.
- 2018-12-31: Deferred Tax Assets, in Process Research and Development $10.65M.
- 2017-12-31: Deferred Tax Assets, in Process Research and Development $9.08M.
- 2016-12-31: Deferred Tax Assets, in Process Research and Development $7.68M.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2019-12-31 | $11.27M 10-K · filed 2020-03-12 |
| 2018-12-31 | $10.65M 10-K · filed 2020-03-12 |
| 2017-12-31 | $9.08M 10-K · filed 2019-03-15 |
| 2016-12-31 | $7.68M 10-K · filed 2018-03-06 |
| 2015-12-31 | $6.54M 10-K · filed 2017-03-13 |
| 2014-12-31 | $5.17M 10-K · filed 2016-02-25 |
| 2013-12-31 | $3.61M 10-K · filed 2015-03-06 |
| 2012-12-31 | $2.33M 10-K · filed 2014-03-06 |